Biotinylated Human B7-H6 / NCR3LG1 Protein, His, Avitag™

The B7 family of genes is essential in the regulation of the adaptive immune system. one of which is the recently discovered B7H6. Humans and rats have a single B7H6 gene; however, many B7H6 genes were detected in a single large cluster in the Xenopus genome. Chimeric antigen receptor (CAR) T-cell therapies have demonstrated durable and potentially curative therapeutic efficacy against B-cell leukemia in clinical trials. In this study, B7H6, a ligand for the NK cell activating receptor NKp30, was targeted to create a CAR that targets multiple tumor types. B7H6 is expressed on various primary human tumors, including leukemia, lymphoma and gastrointestinal stromal tumors, but it is not constitutively expressed on normal tissues.

Product Specifications

Background

Specifications

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™) . The protein has a calculated MW of 30.4 kDa. The protein migrates as 40-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Accession Number

Q68D85-1

Expression Region

Asp 25 - Ser 262

Host

HEK293

Target

B7-H6

Conjugation

Biotin-labeled

Tag

C-10xHis & C-Avi

Source

Human

Stability

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Endotoxin

1.0 EU per μg

Purity

90%

Bioactivity

Immobilized Biotinylated Human B7-H6, His,Avitag (Cat. No. B76-H82E5) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human NKp30, Fc Tag (Cat. No. NC3-H5259) with a linear range of 0.2-2 ng/mL (Routinely tested).